Universal influenza A vaccine: Optimization of M2-based constructs

Virology

Volumn 337, Issue 1, 2005, Pages 149-161

  De Filette, Marina ^a   Jou, Willy Min ^a   Birkett, Ashley ^b   Lyons, Katie ^b   Schultz, Brian ^b   Tonkyro, Anne ^b   Resch, Stephanie ^b   Fiers, Walter ^a  

^a GHENT UNIVERSITY   (Belgium)

^b Apovia Inc   (United States)

Author keywords

HBV core; Hepatitis B virus; Influenza A; M2 protein; M2e HBc

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC LINKAGE; HEPATITIS B VIRUS; IMMUNOGENICITY; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; VIRAL MATRIX PROTEINS;

HEPATITIS B VIRUS;

EID: 19444368726     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2005.04.004     Document Type: Article

References (55)

1. D.G. Altman Practical Statistics for Medical Research 1991 Chapman & Hall London
2. Anonymous, 2003. WHO-CSR, Update 94, July 3 (http://www.who.int/csr/don/ 2003_07_03).
3. Anonymous, 2004. WHO-CSR, Update Dec. 30 (http://www.who.int/csr/don/ 2004_12_30/en/).
4. J. Aucouturier, L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines Expert Rev. Vaccines 1 2002 111 118
5. R.A. Black, P.A. Rota, N. Gorodkova, H.D. Klenk, and A.P. Kendal Antibody response to the M2 protein of influenza A virus expressed in insect cells J. Gen. Virol. 74 1993 143 146
6. A. Birkett PCT Applications WO 99/40934 and WO 02/14478 1999
7. A. Birkett, K. Lyons, A. Schmidt, D. Boyd, G.A. Oliveira, A. Siddique, R. Nussenzweig, J.M. Calvo-Calle, and E. Nardin A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts Infect. Immun. 70 2002 6860 6870
8. C.B. Bridges, W.W. Thompson, M.I. Meltzer, G.R. Reeve, W.J. Talamonti, N.J. Cox, H.A. Lilac, H. Hall, A. Klimov, and K. Fukuda Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial JAMA 284 2000 1655 1663
9. E.C. Claas, A.D. Osterhaus, R. van Beek, J.C. De Jong, G.F. Rimmelzwaan, D.A. Senne, S. Krauss, K.F. Shortridge, and R.G. Webster Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus Lancet 351 1998 472 477
10. N.J. Cox, and K. Subbarao Influenza Lancet 354 1999 1277 1282
11. B.L. Dickinson, and J.D. Clements Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity Infect. Immun. 63 1995 1617 1623
12. J.T. Evans, C.W. Cluff, D.A. Johnson, M.J. Lacy, D.H. Persing, and J.R. Baldridge Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529 Expert Rev. Vaccines 2 2003 89 99
13. J. Fan, X. Liang, M.S. Horton, H.C. Perry, M.P. Citron, G.J. Heidecker, TM. Fu, J. Joyce, C.T. Przysiecki, P.M. Keller, V.M. Garsky, R. Ionescu, Y. Rippeon, L. Shi, M.A. Chastain, J.H. Condra, M.E. Davies, J. Liao, E.A. Emini, and J.W. Shiver Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys Vaccine 22 2004 2993 3003
14. W. Fiers, S. Neirynck, T. Deroo, X. Saelens, and W. Min Jou Soluble recombinant influenza vaccines Philos. Trans. R. Soc. Lond., B Biol. Sci. 356 2001 1961 1963
15. W. Fiers, M. De Filette, A. Birkett, S. Neirynck, and W. Min Jou A "universal" human influenza A vaccine Virus Res. 103 2004 173 176
16. A.M. Frace, A.I. Klimov, T. Rowe, R.A. Black, and J.M. Katz Modified M2 proteins produce heterotypic immunity against influenza A virus Vaccine 17 1999 2237 2244
17. L.C. Freytag, and J.D. Clements Bacterial toxins as mucosal adjuvants Curr. Top. Microbiol. Immunol. 236 1999 215 236
18. C. Gerdil The annual production cycle for influenza vaccine Vaccine 21 2003 1776 1779
19. L.J. Holsinger, and R.A. Lamb Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds Virology 183 1991 32 43
20. V.C. Huber, J.M. Lynch, D.J. Bucher, J. Le, and D.W. Metzger Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections J. Immunol. 166 12 2001 7381 7388
21. A. Jegerlehner, A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, T. Bachi, T. Storni, G. Jennings, P. Pumpens, W.A. Renner, and M.F. Bachmann A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses Vaccine 20 2002 3104 3112
22. A. Jegerlehner, N. Schmitz, T. Storni, and M.F. Bachmann Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity J. Immunol. 172 2004 5598 5605
23. N.P. Johnson, and J. Mueller Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic Bull Hist Med. 6 2002 105 115
24. K.L. Kotloff, M.B. Sztein, S.S. Wasserman, G.A. Losonsky, S.C. DiLorenzo, and R.I. Walker Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection Infect Immun. 69 2001 3581 3890
25. P.A. Kratz, B. Bottcher, and M. Nassal Native display of complete foreign protein domains on the surface of hepatitis B virus capsids Proc. Natl. Acad. Sci. U.S.A. 96 1999 1915 1920
26. R.A. Lamb, C.J. Lai, and P.W. Choppin Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins Proc. Natl. Acad. Sci. U.S.A. 78 1981 4170 4174
27. R.A. Lamb, S.L. Zebedee, and C.D. Richardson Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface Cell 40 1985 627 633
28. B. Liang, L. Hyland, and S. Hou Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice J. Virol. 75 2001 5416 5420
29. W. Liu, H. Li, and Y.H. Chen N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication FEMS Immunol. Med. Microbiol. 35 2003 141 146
30. W. Liu, Z. Peng, Z. Liu, Y. Lu, J. Ding, and Y.H. Chen High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity Vaccine 23 2004 366 371
31. G.A. Losonsky, K.L. Kotloff, and R.I. Walker B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H. pylori seronegative individuals Vaccine 21 2003 562 565
32. X. Lu, J.D. Clements, and J.M. Katz Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine Vaccine 20 2002 1019 1029
33. D.R. Milich, and A. McLachlan The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen Science 234 1986 1398 1401
34. K. Mozdzanowska, J. Feng, M. Eid, G. Kragol, M. Cudic, L.Jr. Otvos, and W. Gerhard Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2 Vaccine 21 2003 2616 2626
35. K. Murray, and A.L. Shiau The core antigen of hepatitis B virus as a carrier for immunogenic peptides Biol. Chem. 380 1999 277 283
36. Neirynck, S., Min Jou, W., Fiers, W., 1997. New immunoprotective influenza antigen and its use in vaccination. Patent application WO99/07839 (18.02.1999); Priority date 1997.08.05.
37. S. Neirynck, T. Deroo, X. Saelens, P. Vanlandschoot, W. Min Jou, and W. Fiers A universal influenza A vaccine based on the extracellular domain of the M2 protein Nat. Med. 5 1999 1157 1163
38. D. Normile WHO ramps up bird flu vaccine efforts Science 303 2004 609
39. A.M. Palache Influenza subunit vaccine-Ten years experience Eur. J. Clin. Res. 3 1992 117 138
40. M.K.B. Palmar, and D. Machin Survival Analysis: a Practical Approach 1995 Wiley New York
41. P.A. Patriarca, J.A. Weber, R.A. Parker, W.N. Hall, A.P. Kendal, D.J. Bregman, and L.B. Schonberger Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic JAMA 53 1985 1136 1139
42. M. Peiris, K.Y. Yuen, C.W. Leung, K.H. Chan, P.L. Ip, R.W. Lai, W.K. Orr, and K.F. Shortridge Human infection with influenza H9N2 Lancet 354 1999 916 917
43. D.H. Persing, R.N. Coler, M.J. Lacy, D.A. Johnson, J.R. Baldridge, R.M. Hershberg, and S.G. Reed Taking toll: lipid A mimetics as adjuvants and immunomodulators Trends Microbiol. 10 2002 S32 S37
44. L.H. Pinto, L.J. Holsinger, and R.A. Lamb Influenza virus M2 protein has ion channel activity Cell 69 1992 517 528
45. G.A. Poland, S.T. Rottinghaus, and R.M. Jacobson Influenza vaccines: a review and rationale for use in developed and underdeveloped countries Vaccine 19 2001 2216 2220
46. P. Pumpens, and E. Grens HBV core particles as a carrier for B cell/T cell epitopes Intervirology 44 2001 98 114
47. J. Salfeld, E. Pfaff, M. Noah, and H. Schaller Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus J. Virol. 63 1989 798 808
48. D.L. Suarez, M.L. Perdue, N. Cox, T. Rowe, C. Bender, J. Huang, and D.E. Swayne Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong J. Virol. 72 1998 6678 6688
49. S. Tamura, T. Iwasaki, A.H. Thompson, H. Asanuma, Z. Chen, Y. Suzuki, C. Aizawa, and T. Kurata Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection J. Gen. Virol. 79 1998 291 299
50. T.M. Tumpey, M. Renshaw, J.D. Clements, and J.M. Katz Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection J. Virol. 75 2001 5141 5150
51. R. Ulrich, M. Nassal, H. Meisel, and D.H. Kruger Core particles of hepatitis B virus as carrier for foreign epitopes Adv. Virus Res. 50 1998 141 182
52. RJ. Webby, D.R. Perez, J.S. Coleman, Y. Guan, J.H. Knight, E.A. Govorkova, L.R. McClain-Moss, J.S. Peiris, J.E. Rehg, EI. Tuomanen, and RG. Webster Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines Lancet 363 2004 1099 1103
53. P.T. Wingfield, S.J. Stahl, R.W. Williams, and A.C. Steven Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly Biochemistry 34 1995 4919 4932
54. S.A. Wynne, R.A. Crowther, and A.G. Leslie The crystal structure of the human hepatitis B virus capsid Mol. Cell 3 1999 771 780
55. J. Zheng, F. Schodel, and D.L. Peterson The structure of hepadnaviral core antigens. Identification of free thiols and determination of the disulfide bonding pattern J. Biol. Chem. 267 1992 9422 9429